What happened
Dongsung Pharmaceutical updated a previously disclosed supply contract with S&BD Korea Co., Ltd., now worth US$8.44M, about 13.4% of its recent annual revenue, running through May 2027.
For context, this single contract equals about 13.4% of the company's most recent annual revenue.
| Counterparty | S&BD Korea Co., Ltd. |
|---|---|
| Contract value | US$8.44M |
| vs. recent revenue | 13.4% |
| Through | May 2027 (from May 2023) |
| Filed | 2026-04-22, [Amended] Supply contract signed |
| Source | DART rcept 20260422800382 → open original filing |
Source: DART. Information only, not investment advice.